• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA grants regenerative medicine advanced therapy status to Mallinckrodt’s StrataGraft

July 18, 2017 By Sarah Faulkner

Mallinckrodt PharmaceuticalsMallinckrodt Pharmaceuticals (NYSE:MNK) said today that its StrataGraft regenerative skin tissue won regenerative medicine advanced therapy status from the FDA.

The tissue-based therapy is among the first products to be granted the designation. The 21st Century Cures Act, which was passed in 2016, enabled the FDA to give accelerated review approval to products that meet RMAT criteria.

To win RMAT status, the product must be a cell therapy, therapeutic tissue engineering product, human cell and tissue product or a combination product that uses such therapies. Additionally, the drug needs to be designed for a serious or life-threatening disease and preliminary clinical results must indicate that it has potential to address unmet medical needs for that disease, according to the FDA.

Mallinckrodt’s StrataGraft is a tissue-based therapy in late-stage trials that is designed to promote autologous skin regeneration in patients with deep partial thickness burns.

“We are very pleased the FDA has determined StrataGraft meets the criteria for RMAT designation, as this offers the possibility of priority review and/or accelerated approval,” chief scientific officer & executive VP Dr. Steven Romano said in prepared remarks. “This provides the potential to bring a much-needed therapeutic option to patients even sooner than originally planned.”

RMAT status allows Mallinckrodt to interact earlier and more frequently with the FDA compared to traditional approval pathways.

“RMAT designation of StrataGraft skin tissue speaks to the strength of the clinical data generated during the prior clinical study,” senior VP of regenerative medicine at Mallinckrodt, Lynn-Allen Hoffman, added. “Mallinckrodt is committed to developing advanced regenerative medicine therapies such as StrataGraft for patients with serious conditions.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regenerative Medicine, Regulatory/Compliance, Wall Street Beat Tagged With: Mallinckrodt Pharmaceuticals

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS